HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma

Valli Re, Laura Caggiari, Lara Mussolin, Emanuele Stefano d'Amore, Barbara Famengo, Mariangela De Zorzi, Lia Martina, Caterina Elia, Marta Pillon, Nicola Santoro, Paola Muggeo, Salvatore Buffardi, Maurizio Bianchi, Alessandra Sala, Piero Farruggia, Luciana Vinti, Edgardo D. Carosella, Roberta Burnelli, Maurizio Mascarin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this study, we tested whether polymorphisms in human leukocyte antigen G (HLA-G) were associated with event-free survival (EFS) in pediatric Hodgkin's lymphoma (HL). We evaluated the association of HLA-G 3'-UTR polymorphisms with EFS in 113 pediatric HL patients treated using the AIEOP LH-2004 protocol. Patients with the +3027-C/A genotype (rs17179101, UTR-7 haplotype) showed lower EFS than those with the +3027-C/C genotype (HR= 3.23, 95%CI: 0.99-10.54, P=0.012). Female patients and systemic B symptomatic patients with the HLA-G +3027 polymorphism showed lower EFS. Multivariate analysis showed that the +3027-A polymorphism (HR 3.17, 95%CI 1.16-8.66, P=0.025) was an independent prognostic factor. Immunohistochemical analysis showed that HL cells from patients with the +3027- C/A genotype did not express HLA-G. Moreover, HLA-G +3027 polymorphism improved EFS prediction when added to the algorithm for therapeutic group classification of pediatric HL patients. Our findings suggest HLA-G +3027 polymorphism is a prognostic marker in pediatric HL patients undergoing treatment according to LH-2004 protocol.

Original languageEnglish
Pages (from-to)105957-105970
Number of pages14
JournalOncotarget
Volume8
Issue number62
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

HLA Antigens
Hodgkin Disease
Pediatrics
Disease-Free Survival
Recurrence
Neoplasms
Genotype
HLA-G Antigens
Untranslated Regions
3' Untranslated Regions
Haplotypes
Multivariate Analysis
Therapeutics

Keywords

  • +3027 C/A genotype
  • 3'UTR polymorphism
  • Event-free survival
  • HLA-G
  • Pediatric hodgkin lymphoma

ASJC Scopus subject areas

  • Oncology

Cite this

HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma. / Re, Valli; Caggiari, Laura; Mussolin, Lara; d'Amore, Emanuele Stefano; Famengo, Barbara; De Zorzi, Mariangela; Martina, Lia; Elia, Caterina; Pillon, Marta; Santoro, Nicola; Muggeo, Paola; Buffardi, Salvatore; Bianchi, Maurizio; Sala, Alessandra; Farruggia, Piero; Vinti, Luciana; Carosella, Edgardo D.; Burnelli, Roberta; Mascarin, Maurizio.

In: Oncotarget, Vol. 8, No. 62, 01.01.2017, p. 105957-105970.

Research output: Contribution to journalArticle

Re, V, Caggiari, L, Mussolin, L, d'Amore, ES, Famengo, B, De Zorzi, M, Martina, L, Elia, C, Pillon, M, Santoro, N, Muggeo, P, Buffardi, S, Bianchi, M, Sala, A, Farruggia, P, Vinti, L, Carosella, ED, Burnelli, R & Mascarin, M 2017, 'HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma', Oncotarget, vol. 8, no. 62, pp. 105957-105970. https://doi.org/10.18632/oncotarget.22515
Re, Valli ; Caggiari, Laura ; Mussolin, Lara ; d'Amore, Emanuele Stefano ; Famengo, Barbara ; De Zorzi, Mariangela ; Martina, Lia ; Elia, Caterina ; Pillon, Marta ; Santoro, Nicola ; Muggeo, Paola ; Buffardi, Salvatore ; Bianchi, Maurizio ; Sala, Alessandra ; Farruggia, Piero ; Vinti, Luciana ; Carosella, Edgardo D. ; Burnelli, Roberta ; Mascarin, Maurizio. / HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma. In: Oncotarget. 2017 ; Vol. 8, No. 62. pp. 105957-105970.
@article{5d6cd50a7d9b48f180334093e7c669c1,
title = "HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma",
abstract = "In this study, we tested whether polymorphisms in human leukocyte antigen G (HLA-G) were associated with event-free survival (EFS) in pediatric Hodgkin's lymphoma (HL). We evaluated the association of HLA-G 3'-UTR polymorphisms with EFS in 113 pediatric HL patients treated using the AIEOP LH-2004 protocol. Patients with the +3027-C/A genotype (rs17179101, UTR-7 haplotype) showed lower EFS than those with the +3027-C/C genotype (HR= 3.23, 95{\%}CI: 0.99-10.54, P=0.012). Female patients and systemic B symptomatic patients with the HLA-G +3027 polymorphism showed lower EFS. Multivariate analysis showed that the +3027-A polymorphism (HR 3.17, 95{\%}CI 1.16-8.66, P=0.025) was an independent prognostic factor. Immunohistochemical analysis showed that HL cells from patients with the +3027- C/A genotype did not express HLA-G. Moreover, HLA-G +3027 polymorphism improved EFS prediction when added to the algorithm for therapeutic group classification of pediatric HL patients. Our findings suggest HLA-G +3027 polymorphism is a prognostic marker in pediatric HL patients undergoing treatment according to LH-2004 protocol.",
keywords = "+3027 C/A genotype, 3'UTR polymorphism, Event-free survival, HLA-G, Pediatric hodgkin lymphoma",
author = "Valli Re and Laura Caggiari and Lara Mussolin and d'Amore, {Emanuele Stefano} and Barbara Famengo and {De Zorzi}, Mariangela and Lia Martina and Caterina Elia and Marta Pillon and Nicola Santoro and Paola Muggeo and Salvatore Buffardi and Maurizio Bianchi and Alessandra Sala and Piero Farruggia and Luciana Vinti and Carosella, {Edgardo D.} and Roberta Burnelli and Maurizio Mascarin",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22515",
language = "English",
volume = "8",
pages = "105957--105970",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "62",

}

TY - JOUR

T1 - HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma

AU - Re, Valli

AU - Caggiari, Laura

AU - Mussolin, Lara

AU - d'Amore, Emanuele Stefano

AU - Famengo, Barbara

AU - De Zorzi, Mariangela

AU - Martina, Lia

AU - Elia, Caterina

AU - Pillon, Marta

AU - Santoro, Nicola

AU - Muggeo, Paola

AU - Buffardi, Salvatore

AU - Bianchi, Maurizio

AU - Sala, Alessandra

AU - Farruggia, Piero

AU - Vinti, Luciana

AU - Carosella, Edgardo D.

AU - Burnelli, Roberta

AU - Mascarin, Maurizio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In this study, we tested whether polymorphisms in human leukocyte antigen G (HLA-G) were associated with event-free survival (EFS) in pediatric Hodgkin's lymphoma (HL). We evaluated the association of HLA-G 3'-UTR polymorphisms with EFS in 113 pediatric HL patients treated using the AIEOP LH-2004 protocol. Patients with the +3027-C/A genotype (rs17179101, UTR-7 haplotype) showed lower EFS than those with the +3027-C/C genotype (HR= 3.23, 95%CI: 0.99-10.54, P=0.012). Female patients and systemic B symptomatic patients with the HLA-G +3027 polymorphism showed lower EFS. Multivariate analysis showed that the +3027-A polymorphism (HR 3.17, 95%CI 1.16-8.66, P=0.025) was an independent prognostic factor. Immunohistochemical analysis showed that HL cells from patients with the +3027- C/A genotype did not express HLA-G. Moreover, HLA-G +3027 polymorphism improved EFS prediction when added to the algorithm for therapeutic group classification of pediatric HL patients. Our findings suggest HLA-G +3027 polymorphism is a prognostic marker in pediatric HL patients undergoing treatment according to LH-2004 protocol.

AB - In this study, we tested whether polymorphisms in human leukocyte antigen G (HLA-G) were associated with event-free survival (EFS) in pediatric Hodgkin's lymphoma (HL). We evaluated the association of HLA-G 3'-UTR polymorphisms with EFS in 113 pediatric HL patients treated using the AIEOP LH-2004 protocol. Patients with the +3027-C/A genotype (rs17179101, UTR-7 haplotype) showed lower EFS than those with the +3027-C/C genotype (HR= 3.23, 95%CI: 0.99-10.54, P=0.012). Female patients and systemic B symptomatic patients with the HLA-G +3027 polymorphism showed lower EFS. Multivariate analysis showed that the +3027-A polymorphism (HR 3.17, 95%CI 1.16-8.66, P=0.025) was an independent prognostic factor. Immunohistochemical analysis showed that HL cells from patients with the +3027- C/A genotype did not express HLA-G. Moreover, HLA-G +3027 polymorphism improved EFS prediction when added to the algorithm for therapeutic group classification of pediatric HL patients. Our findings suggest HLA-G +3027 polymorphism is a prognostic marker in pediatric HL patients undergoing treatment according to LH-2004 protocol.

KW - +3027 C/A genotype

KW - 3'UTR polymorphism

KW - Event-free survival

KW - HLA-G

KW - Pediatric hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85036512705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036512705&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22515

DO - 10.18632/oncotarget.22515

M3 - Article

VL - 8

SP - 105957

EP - 105970

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 62

ER -